$7.50
$15.50
bear $7.50
base $13.00
bull $15.50
margin of safety $5.75
market price* $108.82
Business condition attached to the margin of safety
Positive, statistically significant topline data from Study 302 and/or Study 304 confirming a meaningful hair-regrowth benefit for VDPHL01 -- which would, for the first time, give a named and evidenced basis to credit future product value beyond cash on hand.
Veradermics (NYSE: MANE) is a dermatologist-founded, late clinical-stage biopharmaceutical company developing VDPHL01, an extended-release oral minoxidil for pattern hair loss. The company has no approved products and no revenue: its entire business today is a single drug candidate moving through two pivotal trials -- Study 302 (male and female cohorts), with topline data expected in the first half of 2026, and Study 304, a confirmatory Phase 3 trial in male patients, with topline data expected in the second half of 2026. We were not able to confirm from the filings available for this analysis whether either readout has occurred or what it showed. Because the drug is not yet approved and the company has no signed licensing or distribution agreement, we cannot responsibly assign any value today to future sales of VDPHL01 -- doing so would mean pricing a coin flip, not a business. That means the only thing we can defend as value here is the company's cash. Following its IPO in the first quarter of 2026 (roughly $295 million in gross proceeds) on top of prior private financings, Veradermics held about $807 million in net cash (cash, cash equivalents and short-term investments, less all liabilities -- there is no debt) as of June 30, 2026, against about 41.8 million shares outstanding. That is roughly $19 per share sitting on the balance sheet today. The company is spending that cash at a rate that has grown quickly: research and development costs rose from $23 million in 2024 to $62 million in 2025 as two pivotal trials ran simultaneously, and cash used in operations was about $72 million in 2025, running at a similar annualized pace in the first half of 2026. None of that spending currently produces revenue, and it will not unless a product is approved and launched -- a process that, even after positive trial data, typically takes another one to two years of regulatory review and commercial preparation. Our three cases differ only in how much of that cash pile gets spent, and how fast, before the company reaches a clear decision point: Bear case (~$7.50/share): spending accelerates toward $100 million a year for roughly six years, consistent with the pace of increase already seen from 2024 to 2025, whether because additional trials or indications are pursued after a disappointing readout or because reaching an approval decision costs more than currently guided. Discounted at 6%, that leaves roughly $7.50 per share of unspent cash. Base case (~$13.00/share): spending continues near its recent run-rate of about $75 million a year for roughly four years, covering the two pivotal studies through to a potential approval decision, without assuming the drug ever generates a dollar of credited revenue. That leaves roughly $13 per share. Bull case (~$15.50/share): spending stays closer to the 2025 level of about $70 million a year, and the company reaches a decision point in roughly two and a half years, preserving more of its cash. This is not a scenario where the drug succeeds commercially -- that outcome cannot be priced until it is real -- it is simply the more capital-disciplined path. In every case the company owes nothing of consequence: its only liabilities are ordinary short-term payables and accruals of about $12 million, already netted against the cash figures above. The going-concern language regulators require every early-stage biotech to discuss appears in the filing, but the company states plainly that it has enough cash to fund operations for at least twelve months -- and at roughly $807 million against $70-100 million of annual spending, its runway is measured in years, not months. What would change this picture: positive, statistically significant topline data from Study 302 or Study 304 confirming VDPHL01's hair-regrowth benefit would, for the first time, give something concrete to value beyond cash -- at that point this analysis should be revisited. We checked whether the cash figure itself might be less solid than it appears -- for instance, whether stock-based compensation, which jumped to about $8.8 million in the first half of 2026 from $1.4 million in all of 2025 after the IPO, signals unusual dilution -- and found nothing that changes the net-cash figure materially, though the faster pace of equity grants is worth watching. Given that even our bull case sits well below today's roughly $19 per share of net cash, and that the company's value today rests entirely on an unresolved binary clinical and regulatory outcome, the margin-of-safety price is set meaningfully below our base case -- around $5.75 per share -- to leave room for spending to run longer than expected before any resolution. Both the price and the case itself warrant revisiting as soon as trial data become public.